Healome Therapeutics closes £2M seed round
Analysis based on 6 articles · First reported Jul 07, 2026 · Last updated Jul 10, 2026
The seed round provides Healome Therapeutics with capital to advance its platform toward clinical trials, potentially capturing a share of the $12 billion ocular surface disease market. The investment signals confidence in the technology from specialized venture capital and rare disease foundations, though the company remains at an early stage with no approved products.
Healome Therapeutics, a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, closed an oversubscribed £2 million seed financing round led by Empirical Systems, with participation from DEBRA Research, Cure EB, Oshen Bio, and existing investor SFC Capital. The proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-human studies expected in 2027. The company's platform addresses poor retention of conventional eye drops by forming a clear, lubricating matrix on the eye, enabling sustained drug delivery. Healome holds five patent families and is targeting dry eye disease, ocular surface inflammation, corneal injury, and rare diseases like Epidermolysis Bullosa (EB). The funding will also accelerate development for EB-associated ocular complications.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard